Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG with Alemtuzumab and Rituximab in High-Risk CLL
NCT01269385Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2011
- Primary completion
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odetiglucan in chronic lymphocytic leukemia (CLL), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 35 days and Proportion of Complete Responses at 5 years. Started Jan 2011; status: completed.
02
Drugs
odetiglucan
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01269385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01269385.